Filtered By:
Nutrition: Diets
Countries: Japan Health

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 137 results found since Jan 2013.

Association between Dietary Manganese Intake and Mortality from Cardiovascular Disease in Japanese Population: The Japan Collaborative Cohort Study
CONCLUSIONS: Our study is the first to show the prospective association between dietary Mn intake and reduced risk of mortality from CVD in the Japanese population.PMID:35082202 | DOI:10.5551/jat.63195
Source: Journal of Atherosclerosis and Thrombosis - January 27, 2022 Category: Cardiology Authors: Ouyang Meishuo Ehab S Eshak Isao Muraki Renzhe Cui Kokoro Shirai Hiroyasu Iso Akiko Tamakoshi Source Type: research

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Genes, Vol. 12, Pages 1537: Influence of Renal Impairment and Genetic Subtypes on Warfarin Control in Japanese Patients
Kazuyuki Nagatsuka The genotypes of vitamin K epoxide reductase complex 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) can influence therapeutic warfarin doses. Conversely, nongenetic factors, especially renal function, are associated with warfarin maintenance doses; however, the optimal algorithm for considering genes and renal dysfunction has not been established. This single-center prospective cohort study aimed to evaluate the factors affecting warfarin maintenance doses and develop pharmacogenetics-guided algorithms, including the factors of renal impairment and others. To commence, 176 outpatients who were prescrib...
Source: Genes - September 28, 2021 Category: Genetics & Stem Cells Authors: Tomotaka Tanaka Masafumi Ihara Kazuki Fukuma Haruko Yamamoto Kazuo Washida Shunsuke Kimura Akiko Kada Shigeki Miyata Toshiyuki Miyata Kazuyuki Nagatsuka Tags: Article Source Type: research

Matcha Green Tea Powder does not Prevent Diet ‐Induced Arteriosclerosis in New Zealand White Rabbits Due to Impaired Reverse Cholesterol Transport
ConclusionLong-term matcha green tea treatment of hypercholesterolemic rabbits caused impaired reverse cholesterol transport and increased vascular stiffness, and susceptibility for atherosclerotic lesion development.This article is protected by copyright. All rights reserved
Source: Molecular Nutrition and Food Research - August 14, 2021 Category: Food Science Authors: Monika Hunjadi, Claudia Sieder, Anja Beierfu ß, Christian Kremser, Bernhard Moriggl, René Welte, Christine Kastner, Demissew Shenegelegn Mern, Andreas Ritsch Tags: Research Article Source Type: research

Associations of total nut and peanut intakes with all-cause and cause-specific mortality in a Japanese community: the Takayama study
Br J Nutr. 2021 Jun 21:1-8. doi: 10.1017/S0007114521002257. Online ahead of print.ABSTRACTNumerous epidemiological studies have suggested that nut intake is associated with a reduced risk of mortality. Although diets and lifestyles differ by regions or races/ethnicities, few studies have investigated the associations among non-white, non-Western populations. We evaluated the associations of total nut and peanut intakes with all-cause and cause-specific mortality in a population-based prospective cohort in Japan. Participants (age: ≥35 years at baseline in 1992; n 31 552) were followed up until death or the end of follow-...
Source: The British Journal of Nutrition - July 6, 2021 Category: Nutrition Authors: Michiyo Yamakawa Keiko Wada Sachi Koda Takahiro Uji Yuma Nakashima Sakiko Onuma Shino Oba Chisato Nagata Source Type: research

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Relationship between tongue pressure and dysphagia diet in patients with acute stroke
by Masahiro Nakamori, Kenichi Ishikawa, Eiji Imamura, Haruna Yamamoto, Keiko Kimura, Tomoko Ayukawa, Tatsuya Mizoue, Shinichi Wakabayashi A dysphagia diet is important for patients with stroke to help manage their nutritional state and prevent aspiration pneumonia. Tongue pressure measurement is a simple, non-invasive, and objective method for diagnosing dysphagia. We hypothesized that tongue pressure may be useful in making a choic e of diet for patients with acute stroke. Using balloon-type equipment, tongue pressure was measured in 80 patients with acute stroke. On admission, a multidisciplinary swallowing team includi...
Source: PLoS One - June 4, 2021 Category: Biomedical Science Authors: Masahiro Nakamori Source Type: research

The Modified Chronic Kidney Disease Epidemiology Collaboration Equation for the Estimated Glomerular Filtration Rate is Better Associated with Comorbidities than Other Equations in Living Kidney Donors in Japan
Conclusion We found that the eGFR/Jm-CKD-EPI correlated better with comorbidities than the eGFR/Jm-eGFR and eGFR/Jm-MDRD in Japanese LKT donors. We recommend using the eGFR/Jm-CKD-EPI for the initial assessment of the renal function in LKT donor candidates when evaluating the presence of associated comorbidities.PMID:33716291 | DOI:10.2169/internalmedicine.6934-20
Source: Internal Medicine - March 15, 2021 Category: Internal Medicine Authors: Shinichi Nishi Shunske Goto Makiko Mieno Takashi Yagisawa Kenji Yuzawa Source Type: research